Can a levonorgestrel intrauterine system (LNG‑IUS) be placed in a woman with adenomyosis who has never had sexual intercourse?

LNG-IUS Placement in Nulligravid Women with Adenomyosis

Yes, you can place a levonorgestrel intrauterine system (LNG-IUS) in a woman with adenomyosis who has never had sexual intercourse—nulliparity and virginity are not contraindications to IUD insertion. 1

Key Evidence Supporting Placement

The CDC Medical Eligibility Criteria explicitly states that past pelvic inflammatory disease, HIV infection, immunosuppression, and nulliparity are NOT contraindications to IUD insertion. 1 The only absolute contraindications (Category 4) are:

• Confirmed or suspected pregnancy 1
• Current breast cancer 1
• Distorted uterine cavity from anatomical abnormalities incompatible with insertion 2, 1
• Current cervical or endometrial cancer awaiting treatment 1
• Active pelvic inflammatory disease, purulent cervicitis, or untreated chlamydia/gonorrhea 1

Clinical Efficacy for Adenomyosis

The LNG-IUS is highly effective for adenomyosis management, with significant reductions in pain scores, menstrual bleeding, and uterine volume. 3 Specifically:

• Pain scores decrease significantly at 12,24, and 36 months post-insertion 3
• Menstrual blood loss reduces by 71-95%, comparable to endometrial ablation 1
• Uterine volume decreases significantly at 12 and 36 months 3
• Dysmenorrhea improves dramatically (VAS scores dropping from 75±13 to 11±11 at 12 months) 4

Pre-Insertion Requirements

Before insertion, you must:

• Perform bimanual examination and cervical inspection to rule out anatomical distortion that would preclude proper placement 1
• Confirm the patient is not pregnant using standard criteria 1
• Screen for sexually transmitted infections according to current guidelines (though sexual history may make this low-yield, still follow protocol) 1
• Assess for uterine fibroids, which may increase expulsion rates but are not contraindications (Category 2) 2, 1

Technical Considerations for Nulliparous Patients

Cervical stenosis may be encountered but does not constitute a contraindication (Category 2). 2 Consider:

• Cervical preparation with misoprostol if significant stenosis is anticipated
• Local anesthesia or paracervical block for patient comfort
• The device can be inserted at any time if reasonably certain the patient is not pregnant 1

Managing Post-Insertion Bleeding

Prescribe NSAIDs for 5-7 days during bleeding episodes as first-line treatment for breakthrough bleeding in the first 3-6 months. 1 If bleeding persists beyond 6 months, consider short-term hormonal treatment with low-dose combined oral contraceptives or estrogen for 10-20 days. 1

Expulsion Risk in Adenomyosis

Women with adenomyosis and enlarged uteri have higher expulsion rates (up to 11-20% in some series versus 0-3% in normal uteri). 2, 5 Counsel the patient about this risk and schedule appropriate follow-up. One innovative approach involves suture fixation of the LNG-IUS during hysteroscopic placement to reduce expulsion risk in enlarged uteri. 5

Long-Term Outcomes

The LNG-IUS offers at least 5 years of treatment following a single intervention, with 66% of patients reporting satisfaction at one year. 6, 4 Systemic progesterone absorption is minimal, making it safer than systemic hormonal options. 1